Dr Reddy’s Lab launches generic eye treatment medication in US
PTI, Jan 27, 2023, 5:13 PM IST
Representative Image (Source: Pexels)
New Delhi: Dr Reddy’s Laboratories on Friday said it has launched Difluprednate Ophthalmic Emulsion, used in the treatment of pain and swelling in the eyes caused by infection or allergy after eye surgery, in the American market.
The company has launched the medication, a generic version of Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, after getting approval from the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a statement.
As per IQVIA data, the Durezol brand and generics had sales of around USD 40 million in the US for the most recent twelve months ending in November 2022. Dr Reddy’s shares on Friday ended 2.78 percent up at Rs 4,321.35 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Air India to offer integrated aircraft maintenance engineering programme
Markets stage sharp recovery; Sensex reclaims 79k level, Nifty surges 557.35 points
Baku climate talks: The ‘X’ factor that could determine future of Global South
Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial
Gautam Adani charged in US with USD 250 mn bribery, fraud
MUST WATCH
Latest Additions
Honouring ex-NASA scientist’s last wish, family donates ancestral house to Meerat varsity
Decide on disqualification petitions against BRS MLAs in reasonable time: HC
Air India to offer integrated aircraft maintenance engineering programme
Awards don’t create value for independent films in India: Manoj Bajpayee
Karnataka bypolls: Outcome crucial for both ruling and oppn camps
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.